BRPI0409730A - tratamento da incontinência - Google Patents

tratamento da incontinência

Info

Publication number
BRPI0409730A
BRPI0409730A BRPI0409730-0A BRPI0409730A BRPI0409730A BR PI0409730 A BRPI0409730 A BR PI0409730A BR PI0409730 A BRPI0409730 A BR PI0409730A BR PI0409730 A BRPI0409730 A BR PI0409730A
Authority
BR
Brazil
Prior art keywords
incontinence
treatment
relates
treating
incontinence treatment
Prior art date
Application number
BRPI0409730-0A
Other languages
English (en)
Inventor
Gordon Mcmurray
Wesley Dennis Miner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33397006&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0409730A publication Critical patent/BRPI0409730A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"TRATAMENTO DA INCONTINêNCIA". A invenção presente refere-se à utilização de agonistas de receptores 5-HT2C para o tratamento da incontinência urinária, de preferência a incontinência mista ou a incontinência urinária de estresse. A invenção também refere-se à utilização de antagonistas de receptores 5-HT2C para o tratamento da retenção de urina. A invenção presente Também refere-se a um método de tratamento da incontinência, a testes para despistar compostos úteis para o tratamento da incontinência, e a métodos para preparar composições para o tratamento da incontinência urinária.
BRPI0409730-0A 2003-04-25 2004-04-21 tratamento da incontinência BRPI0409730A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309533 2003-04-25
PCT/IB2004/001437 WO2004096196A2 (en) 2003-04-25 2004-04-21 Treatment of incontinence with 5htc2 agonists

Publications (1)

Publication Number Publication Date
BRPI0409730A true BRPI0409730A (pt) 2006-05-09

Family

ID=33397006

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409730-0A BRPI0409730A (pt) 2003-04-25 2004-04-21 tratamento da incontinência

Country Status (13)

Country Link
EP (2) EP1620081A2 (pt)
JP (2) JP2006524679A (pt)
KR (3) KR20100103726A (pt)
CN (1) CN1780612B (pt)
AU (2) AU2004233745B2 (pt)
BR (1) BRPI0409730A (pt)
CA (2) CA2670067A1 (pt)
CL (1) CL2004000826A1 (pt)
MX (1) MXPA05011410A (pt)
MY (1) MY142857A (pt)
TW (1) TW200426142A (pt)
WO (1) WO2004096196A2 (pt)
ZA (1) ZA200507158B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
WO2007015157A2 (en) * 2005-08-01 2007-02-08 Pfizer Limited Mc4r-ag0nists for the treatment of urinary tract dysfunction
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2008007664A1 (fr) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique bicycique et son utilisation
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
WO2009063993A1 (ja) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
JP5361733B2 (ja) 2007-11-15 2013-12-04 武田薬品工業株式会社 ピリドオキサゼピン誘導体およびその用途
TW201529584A (zh) 2009-06-15 2015-08-01 Takeda Pharmaceutical 吡並氮雜氧雜環庚烯衍生物
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2012002583A1 (en) * 2010-07-02 2012-01-05 Vanderbilt University Method for treating schizophrenia and related diseases with a combination therapy
EP2824106B1 (en) 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2044854A1 (en) 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW270114B (pt) 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
AU5343298A (en) 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
DK0863136T3 (da) 1997-02-25 2004-02-02 Akzo Nobel Nv Azetidin- og pyrrolidinderivater
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU727654B2 (en) 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
JP4422331B2 (ja) * 1998-02-26 2010-02-24 ナームローゼ・フエンノートチヤツプ・オルガノン アゼチジン誘導体およびピロリジン誘導体
AU4037699A (en) 1998-05-08 1999-11-29 Akzo Nobel N.V. Novel aryl-hydro naphthalenal kanamines
GB9819032D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819020D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
WO2000028993A1 (en) 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
AR022687A1 (es) 1998-12-17 2002-09-04 Wyeth Corp Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos.
JP2002535396A (ja) 1999-01-27 2002-10-22 イーライ・リリー・アンド・カンパニー セロトニン（５−ｈｔ（２ｃ））アゴニストとしてのアミノアルキルベンゾフラン類
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
MXPA01011905A (es) 1999-05-21 2004-03-19 Biovitrum Ab Compuestos novedosos, su uso y preparacion.
SE9901884D0 (sv) * 1999-05-21 1999-05-21 Pharmacia & Upjohn Ab Novel compounds their use and preparation
IL145998A0 (en) 1999-06-15 2002-07-25 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
US20030004207A1 (en) 1999-11-29 2003-01-02 Douglas A. Craig Use of compounds which activate a 5-ht receptor to treat urinary incontinence
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
NZ521389A (en) 2000-03-14 2005-06-24 Upjohn Co 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds
WO2001083487A1 (fr) 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derive de froindazole
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
NZ525700A (en) * 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
CA2449899C (en) * 2000-11-20 2010-04-06 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
EP1399445B9 (en) 2000-12-20 2010-07-21 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
PL366233A1 (en) 2000-12-20 2005-01-24 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
WO2002051844A1 (en) 2000-12-27 2002-07-04 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
JPWO2002074746A1 (ja) 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
MXPA04000036A (es) 2001-07-05 2004-05-21 Upjohn Co Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
EP1414826A1 (en) 2001-08-06 2004-05-06 PHARMACIA & UPJOHN COMPANY Therapeutically useful tetracyclic ligands
ES2250689T3 (es) 2001-08-08 2006-04-16 PHARMACIA & UPJOHN COMPANY LLC 1h-pirido(4,3-b)indoles terapeuticos.
US6887868B2 (en) 2001-09-21 2005-05-03 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
MXPA04003594A (es) * 2001-10-18 2004-07-30 Upjohn Co Azaindoles e indolinas tetraciclicas que tienen actividad en serotonina 5-ht-2.
AU2002367323A1 (en) 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation Benzothieno (3,2-
MXPA04005847A (es) 2001-12-28 2004-09-13 Bayer Pharmaceuticals Corp Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
AU2002360819A1 (en) 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
CA2471880A1 (en) 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
CN100484933C (zh) 2002-06-19 2009-05-06 比奥维特罗姆股份公开公司 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途

Also Published As

Publication number Publication date
AU2004233745B2 (en) 2010-03-25
CA2523379C (en) 2010-06-22
CA2670067A1 (en) 2004-11-11
CN1780612A (zh) 2006-05-31
KR20070108921A (ko) 2007-11-13
KR20100103726A (ko) 2010-09-27
AU2004233745A1 (en) 2004-11-11
JP2011064695A (ja) 2011-03-31
EP1620081A2 (en) 2006-02-01
ZA200507158B (en) 2006-11-29
CN1780612B (zh) 2010-12-01
EP2277513A3 (en) 2011-09-07
TW200426142A (en) 2004-12-01
MY142857A (en) 2011-01-14
WO2004096196A2 (en) 2004-11-11
KR20060006063A (ko) 2006-01-18
CA2523379A1 (en) 2004-11-11
AU2010203093A1 (en) 2010-08-12
JP2006524679A (ja) 2006-11-02
MXPA05011410A (es) 2005-12-12
WO2004096196A3 (en) 2005-03-10
CL2004000826A1 (es) 2005-03-04
EP2277513A2 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
BRPI0409730A (pt) tratamento da incontinência
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
BRPI0418092A (pt) combinação terapêutica para melhora cognitiva e transtornos psicóticos
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
DE69728585D1 (de) Mittel gegen Juckreiz
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
PT1199069E (pt) Utilização de um agonista/antagonista de estrogénio para melhoramento ou manutenção da saúde urogenital
NO20022655D0 (no) <Beta>-2-adrenerge reseptoragonister
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr
BR0308391A (pt) Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores
UY26656A1 (es) "metabolitos agonistas/antagonistas de estrogeno"
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
BR0307903A (pt) derivados de arilsulfona
AU3422800A (en) Use of 5-ht3 receptor antagonists
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
DK1000059T3 (da) Tricycliske vasopressin-agonister
ATE353886T1 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase
FR2895259B1 (fr) Methodes de traitement des incontinences urinaires
BRPI0412268A (pt) compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.